TITLE

Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature

AUTHOR(S)
Charneski, Lisa; Congdon, Heather Brennan
PUB. DATE
June 2010
SOURCE
American Journal of Health-System Pharmacy;6/1/2010, Vol. 67 Issue 11, p895
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease are reviewed. Summary. Sickle cell disease is a chronic, inherited disorder characterized by chronic hemolytic anemia and vasoocclusive crisis. Evidence suggests that circulating platelets in patients with sickle cell disease are chronically activated. It is not known whether this is a result of the overall hypercoagulable state or related to the process of vasoocclusion. The extent to which hypercoagulability contributes to vasoocclusion is unknown but makes the use of antiplatelet and anticoagulant medications seem intuitive for preventing and treating vasoocclusive and thrombotic complications of sickle cell disease. Multiple studies have been conducted to determine the effects of antiplatelet and anticoagulant medication on the vasoocclusive and thrombotic complications of sickle cell disease, but many studies were poorly designed, and all were small or uncontrolled. Based on limited data and poorly designed trials, no compelling data exist at this time to recommend aspirin, dipyridamole, ticlopidine, heparin, or vitamin K antagonists for the prevention of vasoocclusive and thrombotic complications in sickle cell disease. For this reason, sickle cell disease should not be used as an independent indication for treatment with an antiplatelet or anticoagulant medication. Clinicians should treat patients with other compelling indications for these therapies according to the American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Conclusion. Based on the existing data, sickle cell disease should not be used as an independent indication for treatment with an antiplatelet or anticoagulant medication.
ACCESSION #
50676896

 

Related Articles

  • Anticoagulation? Antiplatelet? What's the Score? Hager, Jonathan // Annals of Internal Medicine;8/4/2015, Vol. 163 Issue 3, p243 

    A letter to the editor is presented in response to the article "The consult guys-anticoagulation? Antiplatelet? What's the score?" by Geno J. Merli in the previous issue.

  • Anticoagulation? Antiplatelet? What's the Score? Merli, Geno J.; Weitz, Howard H. // Annals of Internal Medicine;8/4/2015, Vol. 163 Issue 3, p243 

    A response from the authors of the article "The consult guys-anticoagulation? Antiplatelet? What's the score?" is presented.

  • Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. Fauchier, Laurent; Greenlaw, Nicola; Ferrari, Roberto; Ford, Ian; Fox, Kim M.; Tardif, Jean-Claude; Tendera, Michal; Steg, Ph. Gabriel; null, null // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: Few data are available regarding the use of antithrombotic strategies in coronary artery disease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the prevalence of AF and its antithrombotic management in a contemporary population of patients with...

  • FIVE THINGS TO KNOW ABOUT... Managing anticoagulation and antiplatelet therapy before interventional radiology procedures. Baerlocher, Mark O.; Myers, Andy; Asch, Murray // CMAJ: Canadian Medical Association Journal;2/8/2011, Vol. 183 Issue 2, p223 

    The article focuses on how to manage anticoagulation and antiplatelet therapy before radiology procedures. It states that patients should undergo testing before radiology procedures to find out their complete blood count. It mentions that reversal agents ensure patient safety, however, they are...

  • Use of Alternative Medicines by Patients with OA that Adversely Interact with Commonly Prescribed Medications. Marsh, Jacquelyn; Hager, Christine; Havey, Tom; Sprague, Sheila; Bhandari, Mohit; Bryant, Dianne // Clinical Orthopaedics & Related Research;Oct2009, Vol. 467 Issue 10, p2705 

    Abstract  Owing to the increasing prevalence, patient interest, and high risk of adverse effects associated with use of complementary and alternative medicine (CAM), investigation of this issue in an orthopaedic population is warranted. The objectives of this study were to (1) identify the...

  • PERIOPERATIVE MANAGEMENT OF ANTITHROMBOTIC THERAPY IN CARDIOVASCULAR PATIENTS. Nuttall, Marc T.; Rodgers, George M. // Methodist DeBakey Cardiovascular Journal;Dec2011, Vol. 7 Issue 4, p10 

    Many patients with underlying cardiovascular disease require long-term anticoagulation. The perioperative or periprocedural management of patients who require temporary interruption of anticoagulant or antiplatelet medications is a common and often challenging clinical problem.1 It requires a...

  • Current management of atrial fibrillation. Samardhi, Himabindu; Santos, Maria; Denman, Russell; Walters, Darren L.; Bett, Nicholas // Australian Prescriber;Aug2011, Vol. 34 Issue 4, p100 

    Atrial fibrillation is a common condition and carries the risk of cerebral thromboembolism. The CHADS2 score is often used to stratify this risk. Anticoagulant therapy with warfarin significantly reduces this risk, but there are limitations to its use. This has prompted the use of antiplatelet...

  • Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation. Edwards, Christine; Shehata, Nadine; Faughnan, Marie // Annals of Hematology;Dec2012, Vol. 91 Issue 12, p1959 

    Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by arteriovenous malformations (AVMs) and hemorrhage. HHT patients can also suffer from unrelated medical conditions requiring anticoagulant or antiplatelet treatment (collectively 'AT'), though...

  • Perioperative Management of Antithrombotic and Antiplatelet Therapy. Bracey, Arthur W. // Texas Heart Institute Journal;May2015, Vol. 42 Issue 3, p239 

    The article explores on the increase use of a long-term anticoagulant therapy in patients with atrial fibrillation in the U.S. Topics discussed include application of oral anticoagulants on inpatient treatment, the coagulation factor activity of warfarin for antithrombotic therapy and the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics